Trade Mark Journal No.2026/042 16 October 2026

WO0000001940267 (5)

Office of origin: United States of America

Date of International Registration:31 August 2026
Date of designation in the UK: 31 August 2026
Image for mark 1940267 ADLIZA

International priority date claimed: 20 April 2026 (Tonga)
Class 5
Pharmaceutical preparations for the treatment of mental health conditions; pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, generalized anxiety disorder (GAD) and major depressive disorder (MDD).

Definium Therapeutics US, Inc.

Representative: John Paul Oleksiuk Cooley LLP, 1299 Pennsylvania Ave. NW STE 700, Washington DC 20004, UNITED STATES OF AMERICA